Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Common Equity (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Common Equity for 6 consecutive years, with $341.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity fell 13.64% year-over-year to $341.7 million, compared with a TTM value of $341.7 million through Dec 2025, down 13.64%, and an annual FY2025 reading of $341.7 million, down 13.64% over the prior year.
  • Common Equity was $341.7 million for Q4 2025 at Cytek Biosciences, down from $378.6 million in the prior quarter.
  • Across five years, Common Equity topped out at $425.5 million in Q4 2022 and bottomed at -$11.0 million in Q2 2021.
  • Average Common Equity over 5 years is $357.8 million, with a median of $394.4 million recorded in 2023.
  • The sharpest move saw Common Equity surged 40644.2% in 2022, then decreased 13.64% in 2025.
  • Year by year, Common Equity stood at $405.4 million in 2021, then grew by 4.97% to $425.5 million in 2022, then dropped by 7.63% to $393.1 million in 2023, then rose by 0.68% to $395.7 million in 2024, then fell by 13.64% to $341.7 million in 2025.
  • Business Quant data shows Common Equity for CTKB at $341.7 million in Q4 2025, $378.6 million in Q3 2025, and $377.6 million in Q2 2025.